{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '14.1.', 'Regulatory and Ethical Considerations', '98', '14.1.1.', 'Regulatory Authority Approvals', '98', '14.1.2.', 'Institutional Review Board and Ethics Committee Approvals', '98', '14.1.3.', 'Subject Informed Consent: Adults', '99', '14.1.4.', 'Subject Informed Consent: Adolescents', '99', '14.1.5.', 'Investigator Reporting Requirements', '100', '14.2.', 'Study Monitoring', '100', '14.3.', 'Quality Assurance', '100', '14.4.', 'Study Termination and Site Closure', '101', '14.5.', 'Records Retention', '101', '14.6.', 'Confidentiality of Information and Data', '102', '14.7.', 'Study Publication', '102', '15.', 'REFERENCES', '103', '16.', 'APPENDICES', '105', '16.1.', 'DMID Adult Toxicity Table (DRAFT, Publish Date: November 2007)', '105', 'LIST OF TABLES', 'Table 1.', 'Abbreviations and Specialist Terms', '22', 'Table 2.', 'Schedule of Assessments: Part 1 of Study BCX7353-302', '54', 'Table 3.', 'Schedule of Assessments: Part 2 of Study BCX7353-302', '58', 'Table 4.', 'Schedule of Assessments: Part 3 of Study BCX7353-302', '60', 'Table 5.', 'Clinical Laboratory Evaluations', '74', 'LIST OF FIGURES', 'Figure 1.', 'Study Schema', '36', 'Figure 2.', 'Study Randomization', '49', '21']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '4.', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', 'Table 1.', 'Abbreviations and Specialist Terms', 'Abbreviation', 'Explanation', 'ABW', 'absolute body weight', 'ACR', 'spot urine microalbumin to creatinine ratio', 'AE', 'adverse event', 'AE-QoL', 'Angioedema Quality of Life Questionnaire', 'ALP', 'alkaline phosphatase', 'ALT', 'alanine aminotransferase', 'API', 'active pharmaceutical ingredient', 'AST', 'aspartate aminotransferase', 'AUC', 'area under the concentration-time curve', 'AUCtau', 'area under the plasma concentration versus time curve over the dosing interval (tau)', 'BK', 'bradykinin', 'BMI', 'body mass index', 'C1-INH', 'C1 esterase inhibitor', 'C3', 'complement 3', 'C4', 'complement 4', 'CBC', 'complete blood count', 'CK', 'creatine kinase', 'CK-MB', 'creatine kinase MB isoenzyme', 'CLCR', 'creatinine clearance', 'Cmax', 'maximum plasma concentration of the drug', 'CRF', 'case report form', 'CRA', 'clinical research associate', 'CSR', 'clinical study report', 'CYP', 'cytochrome P450', 'DLCO', 'diffusion capacity of carbon monoxide', 'DMC', 'Data Monitoring Committee', 'DMID', 'Division of Microbiology and Infectious Diseases', 'ECG', 'Electrocardiogram', 'e-diary', 'electronic diary', 'EOSI', 'event of special interest', 'EQ-5D-5L', 'EuroQoL 5-dimensional, 5-level questionnaire', 'EU', 'European Union', 'FAS', 'Full Analysis Set', 'FDA', 'Food and Drug Administration', 'FSH', 'follicle-stimulating hormone', 'GCP', 'Good Clinical Practice', 'GGT', 'gamma-glutamyltranspeptidase', 'GI', 'gastrointestinal', 'HAE', 'hereditary angioedema', '22']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'Abbreviation', 'Explanation', 'HBV', 'hepatitis B virus', 'HCV', 'hepatitis C virus', 'HIPAA', 'Health Insurance Portability and Accountability Act', 'HIV', 'human immunodeficiency virus', 'HK', 'high-molecular weight kininogen', 'HLA', 'human leukocyte antigen', 'IB', \"Investigator's Brochure\", 'ICF', 'informed consent form', 'ICH', 'International Council for Harmonization', 'IEC', 'independent ethics committee', 'IMP', 'investigational medicinal product (study drug)', 'INR', 'international normalized ratio', 'IRB', 'institutional review board', 'ITT', 'intent to treat', 'IUD', 'intrauterine device', 'IUS', 'intrauterine system', 'IV', 'Intravenous', 'IXRS', 'interactive (web or voice) response system', 'LLN', 'lower limit of normal', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MMRM', 'mixed model of repeated measures', 'NGAL', 'neutrophil gelatinase-associated lipocalin', 'NHP', 'nonhuman primate', 'NOAEL', 'no observed adverse effect level', 'PBMC', 'peripheral blood mononuclear cell', 'PD', 'pharmacodynamic', 'P-gp', 'p-glycoprotein efflux pump', 'PK', 'pharmacokinetic', 'PKK', 'Prekallikrein', 'PLD', 'phospholipidosis', 'PP', 'per protocol', 'PR', 'electrocardiographic interval occurring between the onset of the P wave and the QRS complex,', 'representing time for atrial and ventricular depolarization, respectively', 'QD', 'once daily', 'QoL', 'quality of life', 'QRS', 'electrocardiographic deflection between the beginning of the Q wave and termination of the', 'S wave, representing the time for ventricular depolarization', 'QT', 'electrocardiographic interval between the beginning of the Q wave and termination of the', 'T wave, representing the time for both ventricular depolarization and repolarization to occur', 'QTc', 'corrected QT interval', 'QTcF', \"QT interval corrected by Fridericia's formula\", 'RR', 'interval between successive heart beats using the R-wave peaks', '23']\n\n###\n\n", "completion": "END"}